FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing
→ Months after the UK’s cost-effectiveness agency NICE had a change of heart on its drug Rubraca — Clovis has announced that the FDA
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
